Skip to main content

What the FDA labels say about taking them together

Aspirin/butalbital/caffeine and probenecid

Aspirin/butalbital/caffeine's FDA label of December 2, 2024 names probenecid in its drug interactions section; the probenecid label PlainMeds reads does not name aspirin/butalbital/caffeine.

Check it at the source: the aspirin/butalbital/caffeine FDA label on DailyMed (effective December 2, 2024, Sandoz Inc); the probenecid FDA label on DailyMed (effective January 5, 2021, Lannett Company, Inc.).

What does the aspirin/butalbital/caffeine label say about probenecid?

Aspirin/butalbital/caffeine label, drug interactions

Butalbital, aspirin, and caffeine capsules may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout.

Source: FDA drug label (Butalbital, aspirin, and caffeine), Sandoz Inc, effective December 2, 2024 (SPL set 0e5e3842-fc6c-4a24-8e5c-522701f7c291), via openFDA; the full label on DailyMed

What does the probenecid label say about aspirin/butalbital/caffeine?

Probenecid's label (effective January 5, 2021) does not name aspirin/butalbital/caffeine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Probenecid), Lannett Company, Inc., effective January 5, 2021 (SPL set ab497fd8-00c3-4364-b003-b39d21fbdf38), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

5Aspirin/butalbital/caffeine generic labelers
6Probenecid generic labelers
Aspirin/butalbital/caffeineProbenecid
Labeled forn/aGout
Boxed warningNoNo
Pharmacy cost (NADAC)$0.948 per capsule 50-325-40 mg capsule$0.636 per tablet 500 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?